Six readers
| reader | found | score |
|---|---|---|
| genetics Open Targets | no genetic evidence; overall 0.21 from other evidence | 0.00 |
| cell type Human Protein Atlas | cell type enhanced, including oligodendrocyte progenitor cells; strongest in proximal tubule cells | 0.75 |
| chemistry Open Targets | hard to drug | 0.00 |
| trials ClinicalTrials.gov | no Parkinson's trials on record: an open field | 1.00 |
| literature PubMed | no papers tie it to Parkinson's yet | 1.00 |
| pathways Reactome | 7 pathways; mostly protein handling | 0.90 |
No case: the score is under the bar. Receipt 1986
Sealed predictions
- PCGF2 in dopamine neurons, braak-0.94 (p 2.1e-4) → -0.10 (p 0.807)receipt 1994
- PCGF2 in oligodendrocytes, braak-0.39 (p 0.298) → +0.46 (p 0.217)receipt 1993
Swarm cases
receipt 1994: PCGF2 in dopamine neurons, braak
- power
- full sample -0.60 (p 0.0080, n 18), 95% CI -0.84 to -0.19. the interval excludes zero: something may be there, smaller than a half can see.
- confounder
- adjusted for sex: -0.61 (p 0.0075, n 18). holds up.
- composition
- dopamine neurons share of nuclei vs axis +0.05 (p 0.854); controlling for it: -0.71 (p 0.0010, n 18). not the mix.
- skeptic
- leave-one-out range -0.74 to -0.56, sign flips 0; without severely affected donors -0.60 (p 0.0080, n 18). robust.
- cell type
- no other cell group does better.
- axis
- no measure beats "tracks Braak Lewy-body stage" for PCGF2 in dopamine neurons.
case closed: nothing better to follow up.
receipt 1993: PCGF2 in oligodendrocytes, braak
- power
- full sample +0.12 (p 0.646, n 18), 95% CI -0.37 to +0.55. the interval is wide: not enough donors to tell.
- confounder
- adjusted for sex: +0.16 (p 0.538, n 18). does not hold up.
- composition
- oligodendrocytes share of nuclei vs axis +0.03 (p 0.915); controlling for it: -0.23 (p 0.369, n 18). could be the mix.
- skeptic
- leave-one-out range +0.02 to +0.26, sign flips 0; without severely affected donors +0.12 (p 0.646, n 18). fragile.
- cell type
- strongest in dopamine neurons: -0.60 (p 0.0080, n 18) vs +0.12 in oligodendrocytes. proposing dopamine neurons.
- axis
- no measure beats "tracks Braak Lewy-body stage" for PCGF2 in oligodendrocytes.
follow-up registered; not confirmed in substantia nigra, an independent cohort.
follow-up PCGF2 · dopamine neurons · braak: substantia nigra, an independent cohort: not measured
Receipts
loading the receipts